Literature DB >> 12775413

Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Pia Kivisäkk1, Corinna Trebst, Jar-Chi Lee, Barbara H Tucky, Richard A Rudick, James J Campbell, Richard M Ransohoff.   

Abstract

Blockade of chemokine receptors (CKRs) has recently emerged as a possible pathway for therapeutic intervention in disease. In the present report, the expression of CCR2, CCR5, and CXCR3, associated with migration of mononuclear cells to inflamed tissue, was determined on CD4+ T cells in a 2-year longitudinal study of healthy volunteers using flow cytometry. Large interindividual variations in the expression of these receptors on CD4+ T cells were observed, whereas levels remained remarkably stable over time within subjects. The expression of CCR2, CCR5, and CXCR3 on CD4+ T cells was directly proportional to percentages of CD45RO(hi)/CD4+ T cells. In addition, highly significant associations between levels of CCR2, CCR5, and CXCR3 on CD4+ T cells were demonstrated in individual subjects, implying a common mechanism for regulating the expression of these CKRs on circulating T cells. These associations were not due to coexpression of CKRs on individual CD45RA-/CD4+ T cells. The results provide insight into the regulation of CKR expression on CD4+ T cells in vivo, and suggest that major fluctuations of CKR expression in individuals are uncommon.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775413     DOI: 10.1080/13550280390201001

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  45 in total

Review 1.  The role of chemokine receptors in primary, effector, and memory immune responses.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Authors:  P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells.

Authors:  J M Frade; M Mellado; G del Real; J C Gutierrez-Ramos; P Lind; C Martinez-A
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

4.  Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling.

Authors:  T Misu; H Onodera; K Fujihara; K Matsushima; O Yoshie; N Okita; S Takase; Y Itoyama
Journal:  J Neuroimmunol       Date:  2001-03-01       Impact factor: 3.478

5.  Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells.

Authors:  F Sallusto; E Kremmer; B Palermo; A Hoy; P Ponath; S Qin; R Förster; M Lipp; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

6.  Rules of chemokine receptor association with T cell polarization in vivo.

Authors:  C H Kim; L Rott; E J Kunkel; M C Genovese; D P Andrew; L Wu; E C Butcher
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 7.  Chemokine receptor antagonism as a new therapy for multiple sclerosis.

Authors:  R M Ransohoff; K B Bacon
Journal:  Expert Opin Investig Drugs       Date:  2000-05       Impact factor: 6.206

8.  Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization.

Authors:  M Loetscher; P Loetscher; N Brass; E Meese; B Moser
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

9.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.

Authors:  L Izikson; R S Klein; I F Charo; H L Weiner; A D Luster
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  4 in total

1.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Authors:  David Butera; Svetlana Marukian; Amy E Iwamaye; Edgardo Hembrador; Thomas J Chambers; Adrian M Di Bisceglie; Edgar D Charles; Andrew H Talal; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

2.  Marked differences in CCR5 expression and activation levels in two South African populations.

Authors:  Anabela C P Picton; Sharon Shalekoff; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

3.  Expression of CCR7 and CD45RA in CD4+ and CD8+ subsets in cerebrospinal fluid of 134 patients with inflammatory and non-inflammatory neurological diseases.

Authors:  Katherine M Mullen; Anne R Gocke; Rameeza Allie; Achilles Ntranos; Inna V Grishkan; Carlos Pardo; Peter A Calabresi
Journal:  J Neuroimmunol       Date:  2012-05-24       Impact factor: 3.478

4.  Changes in histone acetylation and methylation that are important for persistent but not transient expression of CCR4 in human CD4+ T cells.

Authors:  Maristela M de Camargo; Hongwei H Zhang; Satya P Singh; John F Foley; Michael N Hedrick; Joshua M Farber
Journal:  Eur J Immunol       Date:  2010-10-20       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.